Core Insights - Thermo Fisher Scientific Inc. (TMO) is a leading biotechnology and life sciences company with a market cap of $220 billion, providing a wide range of products and services for research, diagnostics, and laboratory operations [1][2] Financial Performance - TMO shares have retreated 2.2% from their 52-week high of $610.97, but have surged 21.8% over the past three months, outperforming the Health Care Select Sector SPDR Fund (XLV), which declined by 16.6% during the same period [3] - Year-to-date, TMO is up 14.9%, lagging behind XLV's 15.4% rise, while over the past 52 weeks, TMO shares have increased by 16.3%, surpassing XLV's 9.2% increase [4] Recent Developments - On November 24, Thermo Fisher priced a €2.1 billion ($2.4 billion) euro-denominated bond offering, which includes €1.0 billion floating-rate notes due 2027 and €1.1 billion ($1.3 billion) fixed-rate notes due 2035, aimed at funding general corporate purposes [5] - Following the bond offering announcement, Thermo Fisher's shares rose by 2% in the next trading session [5] Competitive Landscape - IDEXX Laboratories, Inc. (IDXX) has outperformed Thermo Fisher, with shares up 85.4% year-to-date and 78.9% over the past 52 weeks [6]